Drug Profile
Tegafur/uracil
Alternative Names: BMS 200604 01; Orzel; UFT; UftoralLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Developer Merck KGaA; Otsuka Pharmaceutical; Taiho Pharmaceutical
- Class Antineoplastics; Nitrogen mustard compounds; Pyrimidinones
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Pancreatic cancer
- Phase III Cervical cancer
- Discontinued Prostate cancer
Most Recent Events
- 05 Nov 2022 Adverse events and efficacy data from a phase III GOTIC-002 LUFT trial in Cervical cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
- 01 May 2021 Taiho Pharmaceutical completes a phase III trial for Colorectal cancer (Adjuvant therapy) in Japan, prior to May 2021 (PO) (UMIN000005594)
- 01 Jul 2011 Taiho Pharmaceutical initiates enrolment in a phase III trial for Colorectal cancer (Adjuvant therapy) in Japan (PO) (UMIN000005594)